LifeMD (LFMD) said Tuesday that it plans to offer "broad, affordable, and streamlined" access to Novo Nordisk's (NVO) weight-loss drug Wegovy.
The company said all doses of Wegovy are available in a pen device to eligible LifeMD patients who are uninsured or do not have weight-loss medication coverage through their insurance provider.
Shares of LifeMD surged 22% in early trading Tuesday.
Price: 7.47, Change: +1.37, Percent Change: +22.46
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。